BILL Holdings Stock (NYSE:BILL), Trade Ideas

BILL Holdings

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Bill.com Holdings

business-2717066_1920

Analyst Color

Equities

News

Downgrades

Price Target

Analyst Ratings

Movers

Trading Ideas

AVDX

BILL

Goldman Sachs analyst downgraded AvidXchange Holdings from Neutral to Sell and decreased price target due to high stock price and competition concerns.

What&#39;s Going On With AvidXchange Stock Monday?

Penny Stocks

Social Media

Small Cap

Markets

Tech

General

GETY

NVDA

Getty Images Holdings (NYSE: GETY) is expanding its footprint in the visual content creation sector through the recent launch of its latest event series, Create By Getty Images.


Getty Images (GETY) Boosts Creator Community With Latest Event

Health Care

WEAV

Weave Communications (NYSE: WEAV) is expanding its footprint in the healthcare sector with its latest announcement of enhanced integration with a prominent electronic health record (EHR) provider, DrChrono, by EverHealth.


Weave (WEAV) Improves DrChrono Integration for SMB Healthcare

BILL Holdings Inc

BILL IDENTITY LTD by BILL IDENTITY LTD

Billerud AB

BillionHappiness

WIIM

LKQ shares are trading lower after the company reported a Q1 earnings miss and cut its FY24 outlook.

<p>JMP Securities  analyst Joe Goodwin   reiterates Model N (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODN#NYSE">MODN</a>) with a Market Perform.</p>


Reiteration

MODN

JMP Securities Reiterates Market Perform on Model N

<p>Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) has outperformed the market over the past 5 years by 6.52% on an annualized basis producing an average annual return of 17.86%. Currently, Riot Platforms has a market capitalization of $2.99 billion. </p>
<p><strong>Buying $100 In RIOT:</strong> If an investor had bought $100 of RIOT stock 5 years ago, it would be worth <strong>$225.23</strong> today based on a price of $11.78 for RIOT at the time of writing.</p>
<h3>Riot Platforms's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713880851_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RIOT

$100 Invested In Riot Platforms 5 Years Ago Would Be Worth This Much Today

<p>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 13.43% on an annualized basis producing an average annual return of 23.78%. Currently, Meta Platforms has a market capitalization of $1.24 trillion. </p>
<p><strong>Buying $100 In META:</strong> If an investor had bought $100 of META stock 10 years ago, it would be worth <strong>$874.40</strong> today based on a price of $490.68 for META at the time of writing.</p>
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713880846_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Meta Platforms Stock In The Last 10 Years

Macro Economic Events

Econ #s

Economics

USA New Home Sales (MoM) For March 8.8% Vs -5.1% Prior

<p>In the preceding three months, 4 analysts have released ratings for Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $97.75, a high estimate of $118.00, and a low estimate of $83.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.16%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713880831_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Addus HomeCare among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Underweight</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$118.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$102.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Addus HomeCare's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Addus HomeCare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Addus HomeCare analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Addus HomeCare Better</h2>
<p>Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.</p>
<h3>Addus HomeCare: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Addus HomeCare displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>11.86%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>7.08%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Addus HomeCare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.81%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Addus HomeCare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.9%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Addus HomeCare's debt-to-equity ratio is below the industry average. With a ratio of <b>0.25</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ADUS

Cracking The Code: Understanding Analyst Reviews For Addus HomeCare

<p><strong>Eastern Bankshares's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBC#NYSE">EBC</a>) short percent of float has risen 3.75% since its last report. The company recently reported that it has <strong>4.84 million shares sold short</strong>, which is 2.77% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 6.16 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Eastern Bankshares Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713880829_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Eastern Bankshares has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Eastern Bankshares's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eastern Bankshares's peer group average for short interest as a percentage of float is 5.13%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Eastern Bankshares?

<p><strong>Hamilton Lane's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NYSE">HLNE</a>) short percent of float has fallen 11.83% since its last report. The company recently reported that it has <strong>876 thousand shares sold short</strong>, which is 2.31% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.21 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Hamilton Lane Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713880823_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Hamilton Lane has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Hamilton Lane's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hamilton Lane's peer group average for short interest as a percentage of float is 2.71%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


HLNE

Looking Into Hamilton Lane's Recent Short Interest

<p>Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) has been analyzed by 17 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Five Below, presenting an average target of $211.29, a high estimate of $245.00, and a low estimate of $170.00. Observing a downward trend, the current average is 5.48% lower than the prior average price target of $223.53. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713880821_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Five Below by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Chuck Grom</td>
<td>Gordon Haskett</td>
<td>Lowers</td>
<td>Accumulate</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$204.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Jeremy Hamblin</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$187.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$245.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Matthew Korn</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Buy</td>
<td>$225.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Nagel</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$200.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matthew Korn</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$222.00</td>
<td>$217.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Five Below. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Five Below compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Five Below's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Five Below's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FIVE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Five Below analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Five Below</h2>
<p>Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise.</p>
<h3>Five Below's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Five Below's revenue growth over a period of 3 months has been noteworthy. As of 31 January, 2024, the company achieved a revenue growth rate of approximately <strong>19.15%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Five Below's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>15.12%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Five Below's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>13.65%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Five Below's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>5.37%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.1</strong>, Five Below adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FIVE

The Analyst Landscape: 17 Takes On Five Below

USA New Home Sales For March 693K Vs 668K Est.; 637K Prior

<p><strong>First American Financial's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) short percent of float has fallen 34.83% since its last report. The company recently reported that it has <strong>1.16 million shares sold short</strong>, which is 1.16% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.62 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>First American Financial Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713880818_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for First American Financial has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing First American Financial's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, First American Financial's peer group average for short interest as a percentage of float is 1.75%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


(FAF) - Analyzing First American Financial's Short Interest

<p>Keybanc  analyst Sophie Karp   downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Overweight to Sector Weight.</p>


NOVA

Keybanc Downgrades Sunnova Energy Intl to Sector Weight

Shares of life sciences tools stocks are trading higher following strong earnings from Danaher.

<p>Loop Capital  analyst Yun Kim   downgrades Matterport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NASDAQ">MTTR</a>) from Buy to Hold and raises the price target from $5 to $5.5.</p>


MTTR

Loop Capital Downgrades Matterport to Hold, Raises Price Target to $5.5

RNAC

Cartesian Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.

<p>https://www.reuters.com/business/autos-transportation/tesla-aims-cut-400-jobs-germany-via-voluntary-programme-2024-04-23/#:~:text=FRANKFURT%2C%20April%2023%20(Reuters),programme%20instead%20of%20forced%20layoffs.</p>


TSLA

'Tesla aims to cut 400 jobs in Germany via voluntary program' -Reuters

<p><strong>Halliburton Company</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported&nbsp;first-quarter 2024 revenue growth&nbsp;of 2.2% year-over-year to $5.804 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38374599/halliburton-announces-first-quarter-2024-results" rel="noreferrer noopener">beating the consensus of $5.668 billion.</a></p>
<p>Completion and Production revenue was $3.4 billion, slightly down from 2023. Operating income rose 3% to $688 million, fueled by diverse global service improvements and higher product sales.</p>
<p>Drilling and Evaluation revenue rose 7% to $2.4 billion, with operating income up 8% at $398 million, driven by increased drilling services in the Middle East and North America despite some regional drops.</p>
<p>HAL&#8217;s North&nbsp;America&nbsp;revenue fell 8% to $2.5 billion due to decreased U.S. pressure pumping and regional wireline activity.</p>
<p>International revenue was $3.3 billion, an increase of 12% YoY, with revenue from Latin America +21%, Europe/Africa +10% and Middle East/Asia +6%.</p>
<p>Total operating income rose 1% to $987 million, and margin contracted by 20 bps to 17%.</p>
<p>The company repurchased ~$250 million of its common stock during the quarter.</p>
<p>Adjusted EPS was $0.76,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $0.74.</a></p>
<p>Operating cash flow stood at $487 million for the quarter compared to $122 million a year ago, and free cash flow was $206 million.</p>
<p>&#8220;Activity in North America recovered from fourth-quarter lows, and our international business delivered its 11th consecutive quarter of year-on-year growth. Our customers&#8217; multi-year activity plans across markets and asset types confirms my confidence in the strength and duration of this upcycle,&#8221; commented Jeff Miller, Chairman, President, and CEO.</p>
<p>In its conference call, Halliburton said it expects 2024 revenue growth in the low double digits.</p>
<p><strong>Price Action:</strong> HAL shares are trading lower by 0.10% at $38.68 at the last check Tuesday.</p>
<p><em>Photo via Wikimedia Commons</em></p>


Earnings

Guidance

Halliburton's Strong International Performance Lifts Q1 Revenue Amid North American Challenges

VLRS

Controladora Vuela shares are trading higher after the company reported better-than-expected Q1 financial results.

<p>Monday, the FDA approved&nbsp;<strong>ImmunityBio Inc&#8217;s</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) Anktiva (N-803, or&nbsp;nogapendekin&nbsp;alfa&nbsp;inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS),&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38368486/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresp" rel="noreferrer noopener">with or without papillary tumors</a>.</p>
<p>The drug is combined with the BCG vaccine, mainly used against tuberculosis and as a&nbsp;common&nbsp;treatment for some forms of bladder cancer.</p>
<p>Last year in May, the FDA issued a complete response letter to&nbsp;Anktiva plus BCG treatment, citing deficiencies related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/05/32341596/stock-loses-50-in-one-trading-session-why-are-immunitybio-shares-tanking-today" rel="noreferrer noopener">contract manufacturing organizations</a>.</p>
<p>&#8220;The FDA&#8217;s approval of ANKTIVA marks our launch of a next-generation immunotherapy beyond checkpoint inhibitors,&#8221; said Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio.&nbsp;</p>
<p>The company says Anktiva is a first-in-class IL-15 agonist immunotherapy for NMIBC and received FDA Breakthrough Therapy Designation and approval based on the safety and efficacy outcome of complete responses (CR) and duration of complete response (DOR).&nbsp;</p>
<p>The CR rate for the 77 evaluable patients was 62%, with the upper end of the confidence interval being 73%.&nbsp;</p>
<p>The duration of the complete response as of the November 2023 cut-off was more than 47 months and is ongoing to date.&nbsp;</p>
<p>The company adds that the prolonged duration of complete response results beyond 24 months with ANKTIVA and BCG&nbsp;exceeds the benchmark&nbsp;for the magnitude of meaningful clinical results suggested by a panel of experts at the IBCG.</p>
<p>The duration of response is ongoing, so the final median duration of response has yet to be determined. 58% of patients with CR had a DOR ≥ 12 months, and 40% had a DOR ≥ 24 months.</p>
<p>Anktiva is expected to be available in the U.S. by mid-May 2024.</p>
<p><strong>Price Action:</strong>&nbsp;IBRX shares are up 4.65% at $5.17 at the last check Tuesday.</p>


Biotech

IBRX

FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies

<p><strong>Jack Fox</strong>, the Pro Bowl punter for the <strong>Detroit Lions</strong> and upcoming speaker at <a href="https://www.benzinga.com/nfldraft/" target="_blank" rel="noreferrer noopener"><strong>Benzinga&#8217;s 2024 Detriot Draft</strong></a><strong> </strong>event, epitomizes the perseverance and excellence of professional sports. </p>
<p>Transitioning from an undrafted player in 2019 to becoming the league&#8217;s highest-paid punter, Fox&#8217;s journey underscores his commitment and prowess on the field. </p>
<p>Initially signing briefly with the Kansas City Chiefs, Fox found his stride with the Lions, where he was quickly recognized for his powerful punting, securing a Pro Bowl selection shortly after his debut season.</p>
<h3 class="wp-block-heading"><strong>Strategic Contract Renewal</strong></h3>
<p>In 2022, Fox reinforced his value to the Lions through a three-year contract extension valued at $11.325 million, highlighting his integral role on the team. His exceptional ability to maintain an average of 49.1 yards per punt has been critical in setting team records and establishing him as a dependable player during strategic plays, including booming fake punts​.</p>
<h3 class="wp-block-heading"><strong>Commitment to Craft and Community</strong></h3>
<p>Fox&#8217;s dedication extends beyond the playing field. He trains intensively in Alabama each offseason to enhance his athletic performance for forthcoming seasons. His community involvement is also notable; he organizes and leads camps for aspiring young punters and kickers in the Detroit area, demonstrating his commitment to developing the next generation of athletes.</p>
<h3 class="wp-block-heading"><strong>Why You Should Attend Benzinga&#8217;s Draft Event</strong></h3>
<p>Benzinga is a leader in the events space. It has the experience to connect its audience with speakers, panelists, and other attendees. The financial media company has organized 32 &#8216;Business Titans&#8217; events and is known globally for its popular, high-profile gatherings.</p>
<p>The Benzinga Sports Business Titans event features a strong lineup of speakers from the sports and business worlds. Each guest will share their journeys of entrepreneurship and investments.</p>
<p>Athletes, social media stars, and business leaders will share advice and provide a behind-the-scenes look at how sports and business often intersect. This event features former and current athletes and critical business voices. Join Benzinga for the 2024 Sports Business Titans.&nbsp;<a href="https://www.benzinga.com/nfldraft/" target="_blank" rel="noreferrer noopener"><strong>Get tickets here</strong></a><strong>.</strong></p>
<p><em>Image: Football.Shutterstock</em></p>


Sports

Events

Star Detroit Lions Punter To Speak At Benzinga's Detroit Draft Event

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Wagering on mid-cap stocks can potentially unlock investment treasures typically overlooked in the bustling market. Nestled between the giants and the upstarts, these stocks, with market capitalizations in the $2 billion to $10 billion range, offer a unique blend of growth potential and stability. The <strong>SPDR S&amp;P Midcap 400 ETF Trust</strong> <a href="https://seekingalpha.com/symbol/MDY/momentum/performance">was up a healthy 20% in 2023</a>, trailing the <strong>S&amp;P 500&rsquo;s</strong> 33% gain, yet still up by 6% YTD.</p>



<p>Moreover, though large-cap stocks dominate headlines and portfolios with brand visibility, and small-caps are lauded for their long-term potential, mid-caps strike a compelling balance. Investors frequently bypass this sweet spot, a decision some experts may deem a mistake. With that said, here are seven mid-cap stocks to buy, offering tremendous upside potential.</p>



<h2>Undervalued Mid-Cap Stocks: Progyny (PGNY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/oversold-stocks-to-buy-300x169.jpg" alt="man in suit holding a tablet with graphic above showing oversold stocks to buy"><div>Source: undefined undefined / Getty Images</div></div><p><strong>Progyny&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pgny-stock-quote/"><strong>PGNY</strong></a>) remains a compelling investment in the fertility benefits sector on the back of its resilient core strengths and growth metrics. Steady growth in sales, an expanding base of covered individuals, and improved service offerings continue to propel PGNY stock upward. Legislative hurdles, such as the Alabama court&rsquo;s ruling, have briefly clouded the horizon. However, swift legislative adaptations and reassurances from the company leadership have alleviated investor concerns.</p>



<p>The company&rsquo;s financial health remains excellent, <a href="https://seekingalpha.com/news/4072693-progyny-non-gaap-eps-of-0_32-beats-0_21-revenue-of-269_94m-misses-4_18m">evidenced by a 26% bump</a> in revenues year-over-year (YOY) during the fourth quarter (Q4). Moreover, its initiation of a $100 million share repurchase program underlines its commitment to shareholder reward. Its role as a leader in fertility benefits, catering to the evolving needs of millennials grappling with fertility issues, anchors its appeal as a long-term investment. The firm&rsquo;s ongoing client and coverage expansion makes it a compelling buy at <a href="https://seekingalpha.com/symbol/PGNY/valuation/metrics">2.64 times forward sales</a>.</p>



<h2>Gaming &amp; Leisure Properties (GLPI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2018/05/glpi-stock-300x169.jpg" alt=""><div>Source: Shutterstock</div></div><p><strong>Gaming &amp; Leisure Properties</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/glpi-stock-quote/"><strong>GLPI</strong></a>) is one of the leading casino-related real estate investment trusts (<a href="https://investorplace.com/stock-quotes/reit-stock-quote/"><strong>REIT</strong></a>). Despite a significant reliance on <strong>PENN Entertainment </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/penn-stock-quote/"><strong>PENN</strong></a>), which operates 34 of its 61 properties, GLPI stock has maintained a stable performance. Its recently released Q4 results showed a revenue surge of 9.7% YOY to $369 million, <a href="https://seekingalpha.com/news/4072631-gaming-and-leisure-properties-ffo-of-0_93-in-line-revenue-of-369m-beats-7_19m">surpassing estimates by $7.19 million</a>. To put things in perspective, the company has consistently outperformed its revenue forecasts for the past twelve consecutive quarters.</p>



<p>This performance underpins the <a href="https://seekingalpha.com/symbol/GLPI/dividends/scorecard">REIT&rsquo;s attractive 6.56% yield</a>, marking nine years of consecutive payout growth. Consequently, the stock has earned a &lsquo;moderate buy&rsquo; rating from Tipranks, with an anticipated 8% upside. The company presents a compelling value proposition by trading at 16.70 times non-GAAP earnings, which is 45% lower than the sector median. Hence, with its consistent track record of beating revenue estimates and its substantial dividend yield, GLPI stock positions itself as an attractive investment.</p>



<h2>Science Applications International (SAIC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/aerospace-300x169.jpg" alt="a private plane inside a hangar is prepared for a flight. represent aerospace stocks"><div>Source: Shutterstock</div></div><p><strong>Science Applications International&nbsp;</strong>(NYSE:<a href="https://investorplace.com/stock-quotes/saic-stock-quote/"><strong>SAIC</strong></a>) has flown under the radar but remains a key player in the aerospace and defense industry. It stands out for its comprehensive solutions in cloud computing, cybersecurity, and digital transformation. Moreover, it caters to a prestigious clientele, including the U.S. Department of Defense, federal civilian agencies, and the intelligence community.</p>



<p>Demonstrating a remarkable financial performance, the firm has consistently outpaced earnings and revenue estimates since the first quarter (Q1) of 2022. The company&rsquo;s third-quarter (Q3) results were particularly impressive, with a Non-GAAP EPS of $2.27, outperforming <a href="https://seekingalpha.com/news/4042715-science-applications-non-gaap-eps-of-2_27-beats-0_58-revenue-of-1_9b-beats-110m">expectations by 58 cents</a>, while sales of $1.9 billion beat forecasts by a substantial $110 million. The estimated backlog, a critical indicator of future revenue, stood at an impressive $23.1 billion at the quarter&rsquo;s end.</p>



<p>Trading at <a href="https://seekingalpha.com/symbol/SAIC/valuation/metrics">merely one times forward sales</a>, SAIC presents a significant value, being 32% below the sector median. As we advance, SAIC will continue to benefit from the consistent demand driven by global cybersecurity challenges and geopolitical unrest.</p>



<h2>Invesco (IVZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ivz-stock-1-300x169.jpg" alt="image of the invesco office building representing insider buying stocks"><div>Source: JHVEPhoto / Shutterstock.com</div></div><p><strong>Invesco&nbsp;</strong>(NYSE:<a href="https://investorplace.com/stock-quotes/ivz-stock-quote/"><strong>IVZ</strong></a>) is a distinguished player in the global asset management sector, showcasing its prowess over the years with its well-diversified business model and formidable passive investment arm. A strategic emphasis on passive products, equities, fixed income, and alternatives is paying dividends, evidenced by recent inflows and strategic prioritization. February was awesome for Invesco, with preliminary <a href="https://seekingalpha.com/news/4078178-invesco-february-aum-rises-3-driven-by-positive-markets-inflows">assets under management (AUM) climbing</a> to $1.63 trillion, reflecting a 3% jump from the previous month due to favorable market returns.</p>



<p>Moreover, its robust net long-term inflows of $1.8 billion further highlight its growth trajectory. With anticipated rate cuts, Invesco&rsquo;s performance is poised for an even more significant boost, likely enhancing its equities share. This financial health and strategic direction position Invesco as an attractive bet at 1.60 times forward sales estimates while <a href="https://seekingalpha.com/symbol/IVZ/valuation/metrics">yielding an eye-catching 5%</a>.</p>



<h2>Lantheus (LNTH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/bank-lending-capital-1600-300x169.jpg" alt="hands at desk near laptop computer, with one hand holding a pile of hundred dollar bills. Bank stocks"><div>Source: shutterstock.com/CC7</div></div><p><strong>Lantheus</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lnth-stock-quote/"><strong>LNTH</strong></a>) is revolutionizing patient care with its advanced AI tools and imaging agents, marking a major stride in the fight against cancer. Through its cutting-edge AI platform designed to interpret scan results and its partnerships in the biotech and pharma industries, Lantheus is a key player in the evolution of healthcare. Moreover, since Q4 2020, the company has consistently outpaced analyst expectations across both lines by comfortable margins.</p>



<p>Its impressive performance last year is shown by a more than 60% surge in Pylarify sales, resulting in a 39% jump in total revenue to $1.3 billion. To put things in perspective, Pylarify is a diagnostic tool in PET imaging for prostate cancer detection. Looking ahead, with its fiscal 2024 sales guidance set <a href="https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2023-financial">between $1.41 billion to $1.44 billion</a> and the radiopharmaceutical sector poised for major expansion, Lantheus remains an excellent pick. It trades at just 9.50 times forward earnings, significantly below the sector median, accentuating its appeal in the burgeoning healthcare tech sector.</p>



<h2>TKO Group (TKO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/strong-buy-stocks-300x169.jpg" alt='A tickerboard of various stocks, all rated "Strong Buy"'><div>Source: Shutterstock</div></div><p><strong>TKO Group</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/tko-stock-quote/"><strong>TKO</strong></a>) emerges as a standout investment, effectively merging the dynamic appeal of the UFC and the WWE&rsquo;s established global presence. The fusion presents an incredible investment proposition, tapping into over a billion households worldwide. Capitalizing on UFC&rsquo;s explosive international expansion and WWE&rsquo;s sturdy fanbase, the company is growing at a rapid pace with impressive profit margins. Its free cash flow <a href="https://seekingalpha.com/symbol/TKO/cash-flow-statement">stands at a remarkable $400 million</a>, yielding an amazing 23.89%.</p>



<p>The UFC-WWE merger sets the stage for remarkable growth through diversified revenue options, including media rights, event ticketing, and branded merchandise. Its unique market positioning with proactive ventures into burgeoning sectors such as online betting underscore its potential for substantial growth. Moreover, according to <em>Tipranks</em>, TKO represents an attractive proposition, attracting a &lsquo;Moderate Buy&rsquo; rating and <a href="https://www.tipranks.com/stocks/tko/forecast">a 29.50% upside potential</a> from its current price.</p>



<h2>Bill Holdings (BILL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/stocks-to-buy-9-300x169.jpg" alt="stock button on a computer keyboard (representing best investments to start 2021. stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Bill Holdings</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/bill-stock-quote/"><strong>BILL</strong></a>) is a trailblazer in the financial software domain, redefining how businesses handle their financial operations. It operates a powerful cloud-based suite tailored for small to medium-sized businesses, streamlining financial workflows with accounts payable/receivable automation, top-tier security features, and invoice management, among other features. Bill&rsquo;s approach to simplifying complex financial tasks has spurred stellar top-line growth and notable strides in reducing net losses.</p>



<p>Kicking off fiscal 2024, Bill announced a 33% and 22.50% sales growth in Q1 and second-quarter (Q2) respectively. signaling robust market demand. Moreover, it beat EPS estimates by four cents and 23 cents respectively in Q1 and Q2. Additionally, the company&nbsp;<a href="https://seekingalpha.com/pr/19618688-bill-reports-second-quarter-fiscal-year-2024-financial-results?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews">now expects adjusted EPS</a>&nbsp;to be <a href="https://seekingalpha.com/news/4064887-bill-stock-surges-after-boosting-earnings-guidance-fiscal-q2-results-impress">in the $2.09 to $2.31 range</a> compared with the $1.86 average analyst estimate.</p>



<p>Furthermore, with a &lsquo;Moderate Buy&rsquo; rating from <em>Tipranks</em> and <a href="https://www.tipranks.com/stocks/bill/forecast">a promising 27% anticipated</a> upside, Bill&rsquo;s stock is an attractive investment in financial software space.</p>



<p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a></em></p>
<div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor&rsquo;s of science degree in applied accounting from Oxford Brookes University.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/the-7-most-undervalued-mid-cap-stocks-to-buy-in-march-2024/">The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Wagering on mid-cap stocks can potentially unlock investment treasures typically overlooked in the bustling market. Nestled between the giants and the upstarts, these stocks, with market capitalizations in the $2 billion to $10 billion range, offer a unique blend of growth potential and stability. The <strong>SPDR S&amp;P Midcap 400 ETF Trust</strong> <a href="https://seekingalpha.com/symbol/MDY/momentum/performance">was up a healthy 20% in 2023</a>, trailing the <strong>S&amp;P 500&rsquo;s</strong> 33% gain, yet still up by 6% YTD.</p>



<p>Moreover, though large-cap stocks dominate headlines and portfolios with brand visibility, and small-caps are lauded for their long-term potential, mid-caps strike a compelling balance. Investors frequently bypass this sweet spot, a decision some experts may deem a mistake. With that said, here are seven mid-cap stocks to buy, offering tremendous upside potential.</p>



<h2>Undervalued Mid-Cap Stocks: Progyny (PGNY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/oversold-stocks-to-buy-300x169.jpg" alt="man in suit holding a tablet with graphic above showing oversold stocks to buy"><div>Source: undefined undefined / Getty Images</div></div><p><strong>Progyny&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pgny-stock-quote/"><strong>PGNY</strong></a>) remains a compelling investment in the fertility benefits sector on the back of its resilient core strengths and growth metrics. Steady growth in sales, an expanding base of covered individuals, and improved service offerings continue to propel PGNY stock upward. Legislative hurdles, such as the Alabama court&rsquo;s ruling, have briefly clouded the horizon. However, swift legislative adaptations and reassurances from the company leadership have alleviated investor concerns.</p>



<p>The company&rsquo;s financial health remains excellent, <a href="https://seekingalpha.com/news/4072693-progyny-non-gaap-eps-of-0_32-beats-0_21-revenue-of-269_94m-misses-4_18m">evidenced by a 26% bump</a> in revenues year-over-year (YOY) during the fourth quarter (Q4). Moreover, its initiation of a $100 million share repurchase program underlines its commitment to shareholder reward. Its role as a leader in fertility benefits, catering to the evolving needs of millennials grappling with fertility issues, anchors its appeal as a long-term investment. The firm&rsquo;s ongoing client and coverage expansion makes it a compelling buy at <a href="https://seekingalpha.com/symbol/PGNY/valuation/metrics">2.64 times forward sales</a>.</p>



<h2>Gaming &amp; Leisure Properties (GLPI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2018/05/glpi-stock-300x169.jpg" alt=""><div>Source: Shutterstock</div></div><p><strong>Gaming &amp; Leisure Properties</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/glpi-stock-quote/"><strong>GLPI</strong></a>) is one of the leading casino-related real estate investment trusts (<a href="https://investorplace.com/stock-quotes/reit-stock-quote/"><strong>REIT</strong></a>). Despite a significant reliance on <strong>PENN Entertainment </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/penn-stock-quote/"><strong>PENN</strong></a>), which operates 34 of its 61 properties, GLPI stock has maintained a stable performance. Its recently released Q4 results showed a revenue surge of 9.7% YOY to $369 million, <a href="https://seekingalpha.com/news/4072631-gaming-and-leisure-properties-ffo-of-0_93-in-line-revenue-of-369m-beats-7_19m">surpassing estimates by $7.19 million</a>. To put things in perspective, the company has consistently outperformed its revenue forecasts for the past twelve consecutive quarters.</p>



<p>This performance underpins the <a href="https://seekingalpha.com/symbol/GLPI/dividends/scorecard">REIT&rsquo;s attractive 6.56% yield</a>, marking nine years of consecutive payout growth. Consequently, the stock has earned a &lsquo;moderate buy&rsquo; rating from Tipranks, with an anticipated 8% upside. The company presents a compelling value proposition by trading at 16.70 times non-GAAP earnings, which is 45% lower than the sector median. Hence, with its consistent track record of beating revenue estimates and its substantial dividend yield, GLPI stock positions itself as an attractive investment.</p>



<h2>Science Applications International (SAIC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/aerospace-300x169.jpg" alt="a private plane inside a hangar is prepared for a flight. represent aerospace stocks"><div>Source: Shutterstock</div></div><p><strong>Science Applications International&nbsp;</strong>(NYSE:<a href="https://investorplace.com/stock-quotes/saic-stock-quote/"><strong>SAIC</strong></a>) has flown under the radar but remains a key player in the aerospace and defense industry. It stands out for its comprehensive solutions in cloud computing, cybersecurity, and digital transformation. Moreover, it caters to a prestigious clientele, including the U.S. Department of Defense, federal civilian agencies, and the intelligence community.</p>



<p>Demonstrating a remarkable financial performance, the firm has consistently outpaced earnings and revenue estimates since the first quarter (Q1) of 2022. The company&rsquo;s third-quarter (Q3) results were particularly impressive, with a Non-GAAP EPS of $2.27, outperforming <a href="https://seekingalpha.com/news/4042715-science-applications-non-gaap-eps-of-2_27-beats-0_58-revenue-of-1_9b-beats-110m">expectations by 58 cents</a>, while sales of $1.9 billion beat forecasts by a substantial $110 million. The estimated backlog, a critical indicator of future revenue, stood at an impressive $23.1 billion at the quarter&rsquo;s end.</p>



<p>Trading at <a href="https://seekingalpha.com/symbol/SAIC/valuation/metrics">merely one times forward sales</a>, SAIC presents a significant value, being 32% below the sector median. As we advance, SAIC will continue to benefit from the consistent demand driven by global cybersecurity challenges and geopolitical unrest.</p>



<h2>Invesco (IVZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ivz-stock-1-300x169.jpg" alt="image of the invesco office building representing insider buying stocks"><div>Source: JHVEPhoto / Shutterstock.com</div></div><p><strong>Invesco&nbsp;</strong>(NYSE:<a href="https://investorplace.com/stock-quotes/ivz-stock-quote/"><strong>IVZ</strong></a>) is a distinguished player in the global asset management sector, showcasing its prowess over the years with its well-diversified business model and formidable passive investment arm. A strategic emphasis on passive products, equities, fixed income, and alternatives is paying dividends, evidenced by recent inflows and strategic prioritization. February was awesome for Invesco, with preliminary <a href="https://seekingalpha.com/news/4078178-invesco-february-aum-rises-3-driven-by-positive-markets-inflows">assets under management (AUM) climbing</a> to $1.63 trillion, reflecting a 3% jump from the previous month due to favorable market returns.</p>



<p>Moreover, its robust net long-term inflows of $1.8 billion further highlight its growth trajectory. With anticipated rate cuts, Invesco&rsquo;s performance is poised for an even more significant boost, likely enhancing its equities share. This financial health and strategic direction position Invesco as an attractive bet at 1.60 times forward sales estimates while <a href="https://seekingalpha.com/symbol/IVZ/valuation/metrics">yielding an eye-catching 5%</a>.</p>



<h2>Lantheus (LNTH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/bank-lending-capital-1600-300x169.jpg" alt="hands at desk near laptop computer, with one hand holding a pile of hundred dollar bills. Bank stocks"><div>Source: shutterstock.com/CC7</div></div><p><strong>Lantheus</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lnth-stock-quote/"><strong>LNTH</strong></a>) is revolutionizing patient care with its advanced AI tools and imaging agents, marking a major stride in the fight against cancer. Through its cutting-edge AI platform designed to interpret scan results and its partnerships in the biotech and pharma industries, Lantheus is a key player in the evolution of healthcare. Moreover, since Q4 2020, the company has consistently outpaced analyst expectations across both lines by comfortable margins.</p>



<p>Its impressive performance last year is shown by a more than 60% surge in Pylarify sales, resulting in a 39% jump in total revenue to $1.3 billion. To put things in perspective, Pylarify is a diagnostic tool in PET imaging for prostate cancer detection. Looking ahead, with its fiscal 2024 sales guidance set <a href="https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-reports-fourth-quarter-and-full-year-2023-financial">between $1.41 billion to $1.44 billion</a> and the radiopharmaceutical sector poised for major expansion, Lantheus remains an excellent pick. It trades at just 9.50 times forward earnings, significantly below the sector median, accentuating its appeal in the burgeoning healthcare tech sector.</p>



<h2>TKO Group (TKO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/strong-buy-stocks-300x169.jpg" alt='A tickerboard of various stocks, all rated "Strong Buy"'><div>Source: Shutterstock</div></div><p><strong>TKO Group</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/tko-stock-quote/"><strong>TKO</strong></a>) emerges as a standout investment, effectively merging the dynamic appeal of the UFC and the WWE&rsquo;s established global presence. The fusion presents an incredible investment proposition, tapping into over a billion households worldwide. Capitalizing on UFC&rsquo;s explosive international expansion and WWE&rsquo;s sturdy fanbase, the company is growing at a rapid pace with impressive profit margins. Its free cash flow <a href="https://seekingalpha.com/symbol/TKO/cash-flow-statement">stands at a remarkable $400 million</a>, yielding an amazing 23.89%.</p>



<p>The UFC-WWE merger sets the stage for remarkable growth through diversified revenue options, including media rights, event ticketing, and branded merchandise. Its unique market positioning with proactive ventures into burgeoning sectors such as online betting underscore its potential for substantial growth. Moreover, according to <em>Tipranks</em>, TKO represents an attractive proposition, attracting a &lsquo;Moderate Buy&rsquo; rating and <a href="https://www.tipranks.com/stocks/tko/forecast">a 29.50% upside potential</a> from its current price.</p>



<h2>Bill Holdings (BILL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/stocks-to-buy-9-300x169.jpg" alt="stock button on a computer keyboard (representing best investments to start 2021. stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Bill Holdings</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/bill-stock-quote/"><strong>BILL</strong></a>) is a trailblazer in the financial software domain, redefining how businesses handle their financial operations. It operates a powerful cloud-based suite tailored for small to medium-sized businesses, streamlining financial workflows with accounts payable/receivable automation, top-tier security features, and invoice management, among other features. Bill&rsquo;s approach to simplifying complex financial tasks has spurred stellar top-line growth and notable strides in reducing net losses.</p>



<p>Kicking off fiscal 2024, Bill announced a 33% and 22.50% sales growth in Q1 and second-quarter (Q2) respectively. signaling robust market demand. Moreover, it beat EPS estimates by four cents and 23 cents respectively in Q1 and Q2. Additionally, the company&nbsp;<a href="https://seekingalpha.com/pr/19618688-bill-reports-second-quarter-fiscal-year-2024-financial-results?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews">now expects adjusted EPS</a>&nbsp;to be <a href="https://seekingalpha.com/news/4064887-bill-stock-surges-after-boosting-earnings-guidance-fiscal-q2-results-impress">in the $2.09 to $2.31 range</a> compared with the $1.86 average analyst estimate.</p>



<p>Furthermore, with a &lsquo;Moderate Buy&rsquo; rating from <em>Tipranks</em> and <a href="https://www.tipranks.com/stocks/bill/forecast">a promising 27% anticipated</a> upside, Bill&rsquo;s stock is an attractive investment in financial software space.</p>



<p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a></em></p>
<div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor&rsquo;s of science degree in applied accounting from Oxford Brookes University.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/the-7-most-undervalued-mid-cap-stocks-to-buy-in-march-2024/">The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BILL Holdings Inc (BILL) stock is lower by -8.26% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver's proprietary ranking system, gives BILL stock a score of  18 out of a possible 100. That rank is  influenced by a long-term technical score of 14. BILL's rank also include

BILL Holdings Inc (BILL) Stock  Falls -0.28% This Week: Is It a Good Pick?

Bill Holdings quickly gains amid takeover speculation

Tracking Lone Pine Capital Portfolio - Q4 2023 Update

BILL Holdings Inc (BILL) is down Monday morning, with the stock losing -2.30% in pre-market trading to 67.14. BILL's short-term technical score of 17 indicates that the stock has traded less bullishly over the last month than 83% of stocks on the market. In the Software - Application industry, which ranks 91 out of 146 ind

BILL Holdings Inc (BILL) has fallen 2.30% Monday In Premarket Trading

Wells Fargo's high-conviction tactical longs and shorts for Q2

BILL cut to Underweight as Wells Fargo cites growing number of risks

Stock winners of Republican policy if Trump wins - GS

BILL Holdings: Avoid This Stock (Rating Downgrade)

ACVA

AGCO

AMZN

ANNX

ASML

ASMLF

AVTE

AXON

BBWI

BKNG

BSQKZ

CEIX

CTRA

CTVA

DOCN

EPAM

FANG

GLBE

GLPI

GOOG

GOOGL

HNRG

IDXX

INSM

LNTH

LPLA

MTDR

PAYO

PAYX

PGNY

PTEN

PYCR

SAIC

SBUX

SIRI

SITE

SQSP

TOST

TSMWF

UPWK

WDAY

YELP

Fintech

Contracts

Press Releases

Adyen Partners With BILL to Provide Advanced Card Issuing Capabilities

BILL Reports Second Quarter Fiscal Year 2024 Financial Results

BILL Maintains #1 Spot on G2's 2024 Best Software Awards for Accounting and Finance Products

BILL to Participate in Upcoming Investor Conferences

Xero Partners with BILL to Deliver Industry-leading Bill Pay Capabilities for Small Businesses

BILL Survey Finds 85% of SMBs Are Enthusiastic About Using AI in Financial Operations

BILL Expands Most Comprehensive Financial Operations Platform for SMBs with Powerful Predictive Cash Flow Tools